ACADIA Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
ACADIA Pharmaceuticals has a total shareholder equity of $431.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $749.0M and $317.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$438.87m |
Equity | US$431.76m |
Total liabilities | US$317.20m |
Total assets | US$748.96m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: DR6's short term assets ($616.1M) exceed its short term liabilities ($254.3M).
Long Term Liabilities: DR6's short term assets ($616.1M) exceed its long term liabilities ($62.9M).
Debt to Equity History and Analysis
Debt Level: DR6 is debt free.
Reducing Debt: DR6 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DR6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DR6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.